Indaptus Therapeutics Q2 EPS $(0.47) Beats $(0.54) Estimate
Portfolio Pulse from Benzinga Newsdesk
Indaptus Therapeutics (NASDAQ:INDP) reported a Q2 EPS of $(0.47), beating the analyst estimate of $(0.54) by 12.96%. This represents a 20.51% increase in losses compared to the same period last year.
August 12, 2024 | 12:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Indaptus Therapeutics reported a Q2 EPS of $(0.47), beating the analyst estimate of $(0.54) by 12.96%. However, this is a 20.51% increase in losses compared to the same period last year.
The better-than-expected EPS is a positive indicator and may lead to a short-term increase in stock price. However, the year-over-year increase in losses could temper investor enthusiasm.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100